Clinical Trials Details

GY028

Phase IB and Randomized Phase II Trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer

Objective

Key eligibility: Grade 1 or 2 recurrent/metastatic endometrial, Measurable disease, NO prior treatment with AKT inhibitor

>>Learn more about this trial

IRB Protocol Number
202304622

Clinical Trial Categories

  • Cancers and Other Neoplasms